Microsatellite instability markers for identifying early-onset colorectal cancers caused by germ-line mutations in DNA mismatch repair genes

被引:29
作者
Mead, Leeanne J.
Jenkins, Mark A.
Young, Joanne
Royce, Simon G.
Smith, Letitia
John, D. James B. St.
Macrae, Finlay
Giles, Graham G.
Hopper, John L. [1 ]
Southey, Melissa C.
机构
[1] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic 3010, Australia
[2] Univ Melbourne, Dept Pathol, Genet Epidemiol Lab, Melbourne, Vic 3010, Australia
[3] Royal Melbourne Hosp, Dept Colorectal Med & Genet, Melbourne, Vic, Australia
[4] Canc Council Victoria, Ctr Canc Epidemiol, Melbourne, Vic, Australia
[5] Queensland Inst Med Res, Brisbane, Qld 4006, Australia
[6] IARC, Lyon, France
关键词
D O I
10.1158/1078-0432.CCR-06-2174
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Microsatellite instability (MSI) testing of colorectal cancer tumors is used as a screening tool to identify patients most likely to be mismatch repair (MMR) gene mutation carriers. We wanted to examine which microsatellite markers currently used to detect MSI best predict early-onset colorectal cancer caused by germ-line mutations in MMR genes. Experimental Design: Invasive primary tumors from a population-based sample of 107 cases of colorectal cancer diagnosed before age 45 years and tested for germ-line mutations in MLH1, MSH2, MSH6, and PMS2 and MMR protein expression were screened for MSI using the National Cancer Institute panel and an expanded 10-microsatellite marker panel. Results: The National Cancer Institute five-marker panel system scored 31 (29%) as (MSI)-M-NCI- High, 13 (12%) as (MSI)-M-NCI-Low, and 63 (59%) as NCIMS-Stable. The 10-marker panel classified 18 (17%) as (MSI)-M-10-High, 17 (16%) as (MSI)-M-10-Low, and 72 (67%) as (MS)-M-10-Stable. Of the 26 cancers that lacked the expression of at least one MMR gene, 24 (92%) were positive for some level of MSI (using either microsatellite panel). The mononucleotide repeats Bat26, Bat40, and Myb were unstable in all (MSI)-M-10-High cancers and all MLH1 and MSH2 mutation carriers (100% sensitive). Bat40 and Bat25 were unstable in Ell] tumors of MSH6 mutation carriers (100% sensitive). Bat40 was unstable in all MMR gene mutation carriers (100% sensitive). By incorporating seven mononucleotide repeats markers into the 10-marker panel, we were able to distinguish the carriers of MSH6 mutations (all scored (MSI)-M-10-Low) from the MLH1 and MSH2 mutation carriers (all scored (MSI)-M-10-High). Conclusions: In early-onset colorectal cancer, a microsatellite panel containing a high proportion of mononuclear repeats can distinguish between tumors caused by MLH1 and MSH2 mutations from those caused by MSH6 mutations.
引用
收藏
页码:2865 / 2869
页数:5
相关论文
共 22 条
[1]   Low somatic K-ras mutation frequency in colorectal cancer diagnosed under the age of 45 years [J].
Alsop, Kathryn ;
Mead, Leeanne ;
Smith, Letitia D. ;
Royce, Simon G. ;
Tesoriero, Andrea A. ;
Young, Joanne P. ;
Haydon, Andrew ;
Grubb, Garry ;
Giles, Graham G. ;
Jenkins, Mark A. ;
Hopper, John L. ;
Southey, Melissa C. .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (10) :1357-1361
[2]  
Armes JE, 1999, CANCER RES, V59, P2011
[3]   Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer [J].
Barnetson, Rebecca A. ;
Tenesa, Albert ;
Farrington, Susan M. ;
Nicholl, Iain D. ;
Cetnarskyj, Roseanne ;
Porteous, Mary E. ;
Campbell, Harry ;
Dunlop, Malcolm G. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (26) :2751-2763
[4]  
Boland CR, 1998, CANCER RES, V58, P5248
[5]   High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability [J].
Davalos, V. ;
Dopeso, H. ;
Velho, S. ;
Ferreira, A. M. ;
Cirnes, L. ;
Diaz-Chico, N. ;
Bilbao, C. ;
Ramirez, R. ;
Rodriguez, G. ;
Falcon, O. ;
Leon, L. ;
Niessen, R. C. ;
Keller, G. ;
Dallenbach-Hellweg, G. ;
Espin, E. ;
Armengol, M. ;
Plaja, A. ;
Perucho, M. ;
Imai, K. ;
Yamamoto, H. ;
Gebert, J. F. ;
Diaz-Chico, J. C. ;
Hofstra, R. M. ;
Woerner, S. M. ;
Seruca, R. ;
Schwartz, S., Jr. ;
Arango, D. .
ONCOGENE, 2007, 26 (02) :308-311
[6]   Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer [J].
Elsaleh, H ;
Joseph, D ;
Grieu, F ;
Zeps, N ;
Spry, N ;
Iacopetta, B .
LANCET, 2000, 355 (9217) :1745-1750
[7]   Microsatellite instability testing in colorectal carcinoma: Choice of markers affects sensitivity of detection of mismatch repair-deficient tumors [J].
Hatch, SB ;
Lightfoot, HM ;
Garwacki, CP ;
Moore, DT ;
Calvo, BF ;
Woosley, JT ;
Sciarrotta, J ;
Funkhouser, WK ;
Farber, RA .
CLINICAL CANCER RESEARCH, 2005, 11 (06) :2180-2187
[8]   Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma [J].
Herman, JG ;
Umar, A ;
Polyak, K ;
Graff, JR ;
Ahuja, N ;
Issa, JPJ ;
Markowitz, S ;
Willson, JKV ;
Hamilton, SR ;
Kinzler, KW ;
Kane, MF ;
Kolodner, RD ;
Vogelstein, B ;
Kunkel, TA ;
Baylin, SB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (12) :6870-6875
[9]  
Hoang JM, 1997, CANCER RES, V57, P300
[10]   After hMSH2 and hMLH1-what next?: Analysis of three-generational, population-based, early-onset colorectal cancer families [J].
Jenkins, MA ;
Baglietto, L ;
Dite, GS ;
Jolley, DJ ;
Southey, MC ;
Whitty, J ;
Mead, LJ ;
John, DJBS ;
Macrae, FA ;
Bishop, DT ;
Venter, DJ ;
Giles, GG ;
Hopper, JL .
INTERNATIONAL JOURNAL OF CANCER, 2002, 102 (02) :166-171